WuXi AppTec's Hong Kong-traded stock jumped 37% as major shareholders JPMorgan Chase, UBS Group, and BlackRock increased their stakes. The company is set to release its half-year earnings on August 3, with high market expectations.
Ronald Fischer, a 70-year-old former anesthesiologist and one of Rhode Island's most-wanted fugitives, was arrested in New York after two decades. He had been living under the alias Richard Graydon, working as a biotech executive, after fleeing his 2005 sexual assault trial.
San Diego-based Axiom Biosciences plans a "contrarian" Hong Kong IPO in 2027, followed by a 2029 U.S. listing, to access sophisticated biotech investors and Asian partners. This move contrasts with the traditional trend of Chinese firms listing in the U.S., highlighting Hong Kong's growing appeal as a biotech fundraising hub despite U.S. market depth.
Axiom Biosciences, a US-based biotech firm developing AI-powered therapies for newborn brain injuries, is targeting a US$200 million initial public offering (IPO) in Hong Kong by 2027, with a secondary listing in the US planned for 2029. CEO Remo Moomiaie-Qajar highlighted Hong Kong's mature market for healthcare listings.
Two US biotech companies, Akston Biosciences and OKAVA Pharmaceuticals, are testing experimental GLP-1 weight-loss treatments for overweight cats, aiming to bring the blockbuster drug class into pet medicine amidst a growing pet obesity problem and increasing owner spending on pet health.
A US congressional advisory panel, the US-China Economic and Security Review Commission, is making its first trip to China in seven years to investigate the national security implications of the two countries' economic and trade relationship. Chairman Randall Schriver stated the trip aims to understand, not reset, the relationship.
China investiert massiv in die Biotechnologie und überholt Europa bei der Entwicklung neuer Medikamente. Experten warnen vor strategischen Abhängigkeiten und fordern mehr Forschung und Investitionen in Europa.
Reed Jobs discusses his oncology-focused venture firm Yosemite, which builds biotech companies from academic research using philanthropy and venture capital. He highlights the firm's progress, the impact of AI on drug discovery and clinical trials, and the potential of targeting previously undruggable genes like p53.
French biotech Abivax raised $920 million, securing cash until 2029 for US launch of its bowel disease drug obefazimod. CEO Marc de Garidel stated the funding allows the company to proceed independently, despite recent takeover speculation and investor concerns over trial data.
In China entwickelt sich ein neuer Wachstumsmarkt namens Longevity, der Medizin, Biotechnologie und Wellness vereint, um ein langes und gesundes Leben zu fördern. Angesichts der schnell alternden Bevölkerung Chinas birgt dieser Markt ein enormes Potenzial.
In China entsteht ein neuer Wachstumsmarkt für "Longevity", der das lange und gesunde Leben durch Medizin, Biotechnologie und Wellness verspricht. Timepie eröffnet "Chinas erste Longevity-Klinik" in Shanghai, während das Land angesichts seiner schnell alternden Bevölkerung ein riesiges Potenzial bietet.
In China entsteht ein neuer Wachstumsmarkt namens Longevity, der Medizin, Biotechnologie und Wellness vereint. Unternehmen wie Timepie eröffnen Kliniken, die das Altern verlangsamen und die Lebensqualität verbessern sollen, um dem demografischen Wandel und der schnell alternden Bevölkerung Chinas Rechnung zu tragen.
Temasek Holdings increased its China exposure by S$10 billion ($7.7 billion) last fiscal year, the largest annual rise in five years. The state investor is shifting its portfolio towards AI, advanced technology, and "hard tech" sectors like robotics and biotech, moving away from consumer and real estate. China is now viewed as a maturing economy requiring selective investment.
In China entwickelt sich ein neuer Wachstumsmarkt namens Longevity, der Medizin, Biotechnologie und Wellness vereint, um ein langes und gesundes Leben zu fördern. Angesichts der schnell alternden Bevölkerung Chinas birgt dieser Markt ein enormes Potenzial.
Novartis übernimmt das britische Biotechunternehmen Myricx Bio für bis zu 1,5 Milliarden US-Dollar, um seine Onkologie-Sparte zu stärken. Myricx Bio entwickelt Antikörper-Wirkstoff-Konjugate, die Resistenzen gegen Krebsmedikamente überwinden sollen.
Mainz's ambition to become a biotech research hub faces challenges as Biontech scales back. The city must balance investment in research with economic diversification and land use concerns.
Novartis übernimmt das britische Biotechunternehmen Myricx Bio für bis zu 1,5 Milliarden US-Dollar, um seine Onkologie-Sparte zu stärken. Myricx Bio entwickelt Antikörper-Wirkstoff-Konjugate, die Resistenzen gegen Krebsmedikamente überwinden sollen.
Chinese AI-driven drug-design firms are rapidly expanding their global presence through cross-border deals, with out-licensing agreements reaching US$75 billion in the first five months of 2026, despite increasing scrutiny from Washington on Chinese biotech companies. A deal between Metis TechBio and Boulevard Bio exemplifies this trend.
The BrioVAD, a compact, magnetically levitated heart pump from China, is being tested in a US clinical trial for advanced heart failure patients. It's the first active implantable medical device from China to gain FDA approval for US trials, aiming to prove its safety and efficacy against the current market leader, HeartMate 3.
Abivax stock surged 39.9% after releasing new data on its ulcerative colitis drug, obefazimod. The data indicated malignancies were in line with normal levels for UC patients, easing concerns from earlier in June. Over 37% of non-responders achieved remission with a 50 mg dose.
Abivax stock surged 39.9% after releasing new data on its ulcerative colitis drug, obefazimod. The data suggests malignancies were in line with normal UC patient levels, and over 37% of non-responders achieved remission with a 50mg dose after 10 months.
Royalty Pharma, the world's largest biopharmaceutical royalty buyer, established its first Asia-Pacific base in Hong Kong. This move aims to capitalize on record Chinese biotech out-licensing deals and offers an alternative financing method amidst US investment restrictions and geopolitical uncertainties.
Abivax shares surged 36% after new Phase 3 trial data showed its drug obefazimod provided clinically meaningful improvements for adults with moderate to severe ulcerative colitis, including non-responders, and confirmed a favorable safety profile.
Goldman Sachs predicts China's rapid aging will boost pharmaceutical and biotech sectors, citing companies like Zai Lab and WuXi XDC Cayman. Conversely, carmakers and tech hardware manufacturers may face challenges due to demographic shifts.
